DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5A

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor agonists; Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase I Crohn's disease
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye-Disorders
  • No development reported Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 14 Sep 2018 Pharmacodynamics data from in vitro studies in Osteoarthritis released by Ampio Pharmaceuticals
  • 03 Aug 2018 US FDA determines the phase III AP-003-C trial for Osteoarthritis to be inadequate and not well controlled
  • 29 May 2018 Ampio has patent protection for DMI 9523 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top